Does Imunon report any disagreements related to the CSO’s retirement?

Imunon states that Khursheed Anwer’s departure as Executive Vice President and Chief Scientific Officer is without any disagreements with management. The company emphasizes a smooth transition, supported by his continued involvement as a consultant under the Retirement and Consulting Agreement through year-end 2026.

Imunon CSO Anwer to Retire, Becomes Consultant

Imunon, Inc. announced that Executive Vice President and Chief Scientific Officer Khursheed Anwer will retire from the company, with his employment ending on February 20, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Imunon, Inc. announced that Executive Vice President and Chief Scientific Officer Khursheed Anwer will retire from the company, with his employment ending on February 20, 2026. His departure is described as being without any disagreements with management.

To support continuity, Imunon and Dr. Anwer entered into a Retirement and Consulting Agreement dated February 4, 2026. From the retirement date through December 31, 2026, he will provide consulting services for a $10,000 monthly retainer, helping transition his responsibilities.

Under the agreement, Dr. Anwer will receive accrued but unpaid salary and reimbursable expenses within 30 days after his retirement date, plus continued payment of his base salary as severance for twelve months and company-paid COBRA coverage for twelve months. These benefits are conditioned on a customary release of claims in Imunon’s favor.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Imunon (IMNN) disclose in this 8-K?

Imunon disclosed that Executive Vice President and Chief Scientific Officer Khursheed Anwer will retire, with his employment ending February 20, 2026. The company states his departure is without disagreements and outlines a transition to a consulting role through December 31, 2026.

When is Imunon CSO Khursheed Anwer’s retirement effective?

Khursheed Anwer’s retirement from his role as Executive Vice President and Chief Scientific Officer is effective February 20, 2026. After that date, he will no longer be an employee but will continue supporting the company as a consultant under a defined Retirement and Consulting Agreement.

What are the key terms of Imunon’s consulting arrangement with Khursheed Anwer?

Following his retirement, Khursheed Anwer will serve as a consultant from February 20, 2026, through December 31, 2026. During this consulting period, Imunon will pay him a monthly retainer of $10,000 in exchange for providing consulting services and assisting with transition of responsibilities.

What severance benefits will Imunon’s retiring CSO receive?

Under the Retirement and Consulting Agreement, Khursheed Anwer will receive continued base salary as severance for twelve months after his February 20, 2026 retirement date, plus company-paid COBRA health coverage for twelve months, alongside payment of accrued but unpaid salary and reimbursable expenses.

Is there a release of claims in Imunon’s Retirement and Consulting Agreement?

Yes. The Retirement and Consulting Agreement between Imunon and Khursheed Anwer is subject to a customary release of claims in the company’s favor. This type of release typically protects the company from future employment-related claims while providing agreed compensation and benefits to the departing executive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/05/2026 - 08:05 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2026

Imunon, Inc.

(Exact name of registrant as specified in its Charter)

Delaware

001-15911

52-1256615

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retirement of Chief Scientific Officer

On February 2, 2026, Khursheed Anwer informed Imunon, Inc. (the “Company”) of his intent to retire as Executive Vice President and Chief Scientific Officer from the Company, and Dr. Anwer’s employment with the Company will end, effective February 20, 2026 (the “Retirement Date”). Dr. Anwer’s departure is without any disagreements with management. To help ensure a smooth transition of his responsibilities, Dr. Anwer and the Company agreed that he will transition to a consulting role with the Company.

On February 4, 2026, the Company and Dr. Anwer entered into a retirement and consulting agreement (the “Retirement and Consulting Agreement”) pursuant to which he will provide the Company consulting services from his Retirement Date until December 31, 2026 (the “Consulting Period”). During the Consulting Period, Dr. Anwer will be paid a monthly retainer of $10,000. In addition, pursuant to the Retirement and Consulting Agreement, Dr. Anwer is entitled to receive (i) within 30 days following his Retirement Date, any accrued but unpaid salary and any unreimbursed business expenses incurred prior to his Retirement Date, (ii) continued payment of his base salary as severance pay for a period of twelve months following the Retirement Date and (iii) Company-paid COBRA coverage for a period of twelve months following the Retirement Date. The Retirement and Consulting Agreement is subject to a customary release of claims in the Company’s favor.

The foregoing description of the Retirement and Consulting Agreement is not complete and is qualified in its entirety by reference to the Retirement and Consulting Agreement, which is filed herewith as Exhibit 10.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

10.1		Retirement and Consulting Agreement, dated February 4, 2026, between Imunon, Inc. and Khursheed Anwer

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON INC.

Dated: February 5, 2026	By:	/s/ Susan Eylward
		Susan Eylward
		General Counsel and Corporate Secretary

Source: View Original Filing on SEC EDGAR